WO2008099804A1 - 糖尿病白内障の治療剤 - Google Patents

糖尿病白内障の治療剤 Download PDF

Info

Publication number
WO2008099804A1
WO2008099804A1 PCT/JP2008/052239 JP2008052239W WO2008099804A1 WO 2008099804 A1 WO2008099804 A1 WO 2008099804A1 JP 2008052239 W JP2008052239 W JP 2008052239W WO 2008099804 A1 WO2008099804 A1 WO 2008099804A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic cataract
therapeutic agent
cataract
activity
antioxidant agent
Prior art date
Application number
PCT/JP2008/052239
Other languages
English (en)
French (fr)
Inventor
Kunio Ishii
Maki Saito
Original Assignee
School Juridical Person Kitasato Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by School Juridical Person Kitasato Institute filed Critical School Juridical Person Kitasato Institute
Publication of WO2008099804A1 publication Critical patent/WO2008099804A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　糖尿病白内障の進行過程に対し効果的な遅延作用を示す糖尿病白内障の治療剤は、網膜の酸化障害を抑制する抗酸化薬を有効成分として含む。この抗酸化薬は、特定の構造を有するフェニルアゾール化合物又はその薬学的に許容される塩でよい。ＮＯラジカルスカベンジ作用及び高い網膜移行性を有する抗酸化薬が効果的な抗糖尿病白内障作用を有することが明らかとなり、それにより、これまで薬物療法が困難であると考えられてきた白内障の新たな治療戦略が提供される。
PCT/JP2008/052239 2007-02-14 2008-02-12 糖尿病白内障の治療剤 WO2008099804A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-032923 2007-02-14
JP2007032923A JP2008195655A (ja) 2007-02-14 2007-02-14 糖尿病白内障の治療剤

Publications (1)

Publication Number Publication Date
WO2008099804A1 true WO2008099804A1 (ja) 2008-08-21

Family

ID=39690033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052239 WO2008099804A1 (ja) 2007-02-14 2008-02-12 糖尿病白内障の治療剤

Country Status (2)

Country Link
JP (1) JP2008195655A (ja)
WO (1) WO2008099804A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292868A1 (en) 2009-08-24 2018-03-14 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
US20160145242A1 (en) * 2013-07-04 2016-05-26 Nippon Soda Co., Ltd. Phenylimidazole derivative, and therapeutic medicine or preventive medicine for inflammatory disease, etc.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301818A (ja) * 1986-12-03 1988-12-08 Takeda Chem Ind Ltd 白内障治療剤
JPH10276721A (ja) * 1997-04-11 1998-10-20 Suntory Ltd アスタキサンチン含有飲食物
JPH11343241A (ja) * 1998-03-31 1999-12-14 Cci Corp 眼疾患予防および治療剤
WO2005012293A1 (ja) * 2003-08-01 2005-02-10 Nippon Soda Co., Ltd. フェニルアゾール化合物、製造法および抗酸化薬

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301818A (ja) * 1986-12-03 1988-12-08 Takeda Chem Ind Ltd 白内障治療剤
JPH10276721A (ja) * 1997-04-11 1998-10-20 Suntory Ltd アスタキサンチン含有飲食物
JPH11343241A (ja) * 1998-03-31 1999-12-14 Cci Corp 眼疾患予防および治療剤
WO2005012293A1 (ja) * 2003-08-01 2005-02-10 Nippon Soda Co., Ltd. フェニルアゾール化合物、製造法および抗酸化薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BILGEN OZMEN ET AL.: "Lens superoxide dismutase and catalase activities in diabetic cataract", CLINICAL BIOCHEMISTRY, vol. 35, 2002, pages 69 - 72 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors

Also Published As

Publication number Publication date
JP2008195655A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2012033792A3 (en) Treatment of diseases
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2009028495A1 (ja) 真菌性皮膚炎用剤
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2012005500A3 (ko) 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
WO2006083780A3 (en) Glucuronidated nebivolol
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2013100567A8 (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
MX2009013062A (es) Derivados de 3´4´,5-trimetoxi flavona como estimulante de secrecion de mucosa, metodo de los mismos, y composicion farmaceutica que comprende los mismos.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2008008701A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2008105507A1 (ja) 脊髄損傷治療薬剤
WO2008099804A1 (ja) 糖尿病白内障の治療剤
WO2007145863A3 (en) Sustained release formulation of naltrexone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711103

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711103

Country of ref document: EP

Kind code of ref document: A1